Cross-institution positioning
Aug 6, 2026Mixed positioning. 1 accumulating, 1 exited across 2 comparable institutions.
Source: Schedule 13 researchLionsgate Studios Corp.
Latest stored close $11.13 as of Oct 9, 2026 View live quote ↗
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
Mixed positioning. 1 accumulating, 1 exited across 2 comparable institutions.
Source: Schedule 13 research1 increased/new, 1 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsOver the last 90 days, SEC-coded non-derivative P/S activity includes 7 purchases by 1 reporting owner and 5 sales by 1 reporting owner. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/54 non-amendment material events in the last 90 days; Latest classified evidence: Shareholder vote results. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataRevenue +47.7% YoY; Net income +73.6% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsRecent close is 49% through its reported 52-week range; +54.1% over one year.
Source: Stored historical price seriesFiled Aug 6, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
See each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Comparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Compare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | FINE EMILY | AGrant, award, or other acquisition | Common Shares | 13.4K | $11.19 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | FINE EMILY | AGrant, award, or other acquisition | Common Shares | 4.5K | $11.19 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | RACHESKY MARK H MD | AGrant, award, or other acquisition | Common Shares | 13.4K | $11.19 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | RACHESKY MARK H MD | AGrant, award, or other acquisition | Common Shares | 6.8K | $11.19 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | Crawford Gordon | AGrant, award, or other acquisition | Common Shares | 4.5K | $11.19 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | Crawford Gordon | AGrant, award, or other acquisition | Common Shares | 13.4K | $0.00 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | HARKEY JOHN D JR | AGrant, award, or other acquisition | Common Shares | 5.8K | $11.19 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | HARKEY JOHN D JR | AGrant, award, or other acquisition | Common Shares | 13.4K | $0.00 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | McCaw Susan | AGrant, award, or other acquisition | Common Shares | 13.4K | $0.00 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | Ostolaza Yvette | AGrant, award, or other acquisition | Common Shares | 5.4K | $11.19 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | Ostolaza Yvette | AGrant, award, or other acquisition | Common Shares | 13.4K | $0.00 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | Rosenblatt M Richard | AGrant, award, or other acquisition | Common Shares | 4.5K | $11.19 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | Rosenblatt M Richard | AGrant, award, or other acquisition | Common Shares | 13.4K | $0.00 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | SLOAN HARRY | AGrant, award, or other acquisition | Common Shares | 5.4K | $11.19 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | SLOAN HARRY | AGrant, award, or other acquisition | Common Shares | 13.4K | $0.00 | Direct | Sep 17, 2026 |
| Jul 8, 2026 | RACHESKY MARK H MD | POpen-market or private purchase | Common Shares | 11.8M | — | Indirect | Jul 10, 2026 |
| Jul 8, 2026 | RACHESKY MARK H MD | SOpen-market or private sale | Common Shares | 11.8M | — | Indirect | Jul 10, 2026 |
| Jul 8, 2026 | RACHESKY MARK H MD | POpen-market or private purchase | Common Shares | 15.8M | — | Indirect | Jul 10, 2026 |
| Jul 8, 2026 | RACHESKY MARK H MD | POpen-market or private purchase | Common Shares | 499.8K | — | Indirect | Jul 10, 2026 |
| Jul 8, 2026 | RACHESKY MARK H MD | SOpen-market or private sale | Common Shares | 499.8K | — | Indirect | Jul 10, 2026 |
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Sep 16, 2026 | 8-K | 5.07, 9.01 | Shareholder vote results; Financial statements / exhibits | — | Filing |
| Aug 6, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Jul 23, 2026 | 8-K | 5.02, 9.01 | Director or executive change; Financial statements / exhibits | — | Filing |
| Jul 6, 2026 | 8-K | 8.01 | Other event | — | Filing |
| Jun 5, 2026 | 424B3 | — | Prospectus filing | Capital-related | Filing |
| May 27, 2026 | S-3 | — | Shelf securities registration | Capital-related | Filing |
| May 21, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Apr 15, 2026 | 424B3 | — | Prospectus filing | Capital-related | Filing |
| Apr 15, 2026 | 8-K | 5.02, 9.01 | Director or executive change; Financial statements / exhibits | — | Filing |
| Mar 18, 2026 | 424B3 | — | Prospectus filing | Capital-related | Filing |
| Mar 18, 2026 | 8-K | 5.07, 9.01 | Shareholder vote results; Financial statements / exhibits | — | Filing |
| Feb 5, 2026 | 424B3 | — | Prospectus filing | Capital-related | Filing |
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
| Period | Revenue | YoY |
|---|---|---|
| Ended Jun 30, 2026 | $776.6M | +47.7% |
| Ended Dec 31, 2025 | $724.3M | +15.3% |
| Ended Sep 30, 2025 | $475.1M | -21.3% |
| Ended Jun 30, 2025 | $525.9M | +8.0% |
| Period | Revenue | YoY |
|---|---|---|
| Ended Mar 31, 2026 | $2.6B | +1.8% |
| Ended Mar 31, 2025 | $2.6B | +5.5% |
| Ended Mar 31, 2024 | $2.5B | -20.5% |
| Ended Mar 31, 2023 | $3.1B | — |
Dated price context from the historical market series already collected for this security.
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Fidelity / FMR CIK0000315066 | Jun 30, 2026 observed Aug 6, 2026 filed · 37d Schedule 13G amendment | Reported accumulation | 19.3K +4.6K | 6.70% -5.30 pts | $15.31 | $12.93 | $11.13 |
| Fidelity / FMR CIK0000315066 | Apr 27, 2026 observed May 1, 2026 filed · 4d Initial Schedule 13G | Initial Schedule 13G | 14.8K | 12.00% | $12.24 | $12.65 | $11.13 |
| Vanguard Group CIK0000102909 | Mar 13, 2026 observed Mar 27, 2026 filed · 14d Schedule 13G amendment | Exit below reporting threshold | 0 -23.6M | 0.00% -8.24 pts | $9.72 | $9.19 | $11.13 |
Compare LION with other securities showing similar institutional activity or recent accumulation across several tracked institutions.